October, 2024
October 2024
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Stephen V Liu: FDA approved MARIPOSA2
Sep 20, 2024, 13:27

Stephen V Liu: FDA approved MARIPOSA2

Stephen V Liu shared on X:

FDA approved MARIPOSA2: amivantamab plus chemotherapy for EGFR NSCLC post osimertinib. Adding amivantamab improves PFS (HR 0.48) with encouraging OS trend (HR 0.73, not yet significant).”

 

Read Further.
Source: Stephen V Liu/X

More posts featuring Stephen V Liu on oncodaily.com

Stephen V Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center. As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies.

His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer. Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.